Hindustan Bio Sciences Ltd vs Shilpa Medicare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Hindustan Bio Sciences Ltd is ₹ 8.96 as of 05 May 15:30 . The P/E Ratio of Hindustan Bio Sciences Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Shilpa Medicare Ltd changed from 18.4 on March 2021 to 82.8 on March 2025 . This represents a CAGR of 35.10% over 5 years The Market Cap of Hindustan Bio Sciences Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Shilpa Medicare Ltd changed from ₹ 2721 crore on March 2021 to ₹ 6483 crore on March 2025 . This represents a CAGR of 18.96% over 5 years The revenue of Hindustan Bio Sciences Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Shilpa Medicare Ltd for the Dec '25 is ₹ 410.54 crore as compare to the Sep '25 revenue of ₹ 371.72 crore. This represent the growth of 10.44% The ebitda of Hindustan Bio Sciences Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Shilpa Medicare Ltd for the Dec '25 is ₹ 101.9 crore as compare to the Sep '25 ebitda of ₹ 109.92 crore. This represent the decline of -7.3% The net profit of Hindustan Bio Sciences Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Shilpa Medicare Ltd changed from ₹ 14.06 crore to ₹ 44.58 crore over 7 quarters. This represents a CAGR of 93.36% The Dividend Payout of Hindustan Bio Sciences Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Shilpa Medicare Ltd changed from 4.86 % on March 2021 to 14.01 % on March 2025 . This represents a CAGR of 23.58% over 5 years .

About Hindustan Bio Sciences Ltd

Hindustan Bio Science Ltd (Formerly known Hindustan Softel Ltd) was incorporated as Public Limited Company on December 16, 1991.
The Company engaged in the manufacturing and sale of pharmaceutical products is an integrated firm with diversified operations in pharmaceutical and biotechnology sectors.
The Company initially commenced operations in 1992 by sourcing bulk drugs (APIs) and drug intermediates for the Industry with a wellspring of global suppliers and associates. Previously, it was engaged in cement manufacturing and due to sluggish in the industry the company diversified its business into Bio Technology & Pharmaceuticals activities and the name of the Company was changed from Garuda Cements to Hindustan Bio-Sciences Ltd. In 2001, it diversified into software field and subsequently changed its name to Hindustan Softel Limited which presently got changed into Hindustan Bio Sciences Ltd.

About Shilpa Medicare Ltd

Shilpa Medicare Limited, formerly known as Shilpa Antibiotics Private Limited was incorporated as a Private Company on November 20, 1987.
The Company changed the status to Public and the name of the Company changed to Shilpa Antibiotics Limited in November, 1993 and later on, was changed to 'Shilpa Medicare Limited' on February 17, 2003. The Company has been promoted by Vishnukant C. Bhutada and his Associates and is engaged in manufacturing of API, Formulation and Development service.
The Company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka.
It then started commercial production in November, 1989. The Company is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology.
It supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets.

FAQs for the comparison of Hindustan Bio Sciences Ltd and Shilpa Medicare Ltd

Which company has a larger market capitalization, Hindustan Bio Sciences Ltd or Shilpa Medicare Ltd?

Market cap of Hindustan Bio Sciences Ltd is 9 Cr while Market cap of Shilpa Medicare Ltd is 8,300 Cr

What are the key factors driving the stock performance of Hindustan Bio Sciences Ltd and Shilpa Medicare Ltd?

The stock performance of Hindustan Bio Sciences Ltd and Shilpa Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Hindustan Bio Sciences Ltd and Shilpa Medicare Ltd?

As of May 5, 2026, the Hindustan Bio Sciences Ltd stock price is INR ₹8.96. On the other hand, Shilpa Medicare Ltd stock price is INR ₹424.4.

How do dividend payouts of Hindustan Bio Sciences Ltd and Shilpa Medicare Ltd compare?

To compare the dividend payouts of Hindustan Bio Sciences Ltd and Shilpa Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.